Regeneron Pharmaceuticals, Inc. REGN
920.69 USD -1.71 (-0.19%)
Regular-session close
920.69 0.00 0.00%
After hours · Nov 20, 6:14 PM ET
916.66 Day range 948.42
600.66 52-week range 973.36
- YTD
- +19.28%
- 1 year
- +24.92%
News
zacks.com Here's Why Regeneron (REGN) is a Strong Momentum Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
benzinga.com Jim Cramer Rejects UiPath Despite Cheap Valuation, Backs Affirm Cramer called UiPath cheap but lacking catalysts, endorsed Karman and Affirm, warned on Onto and Nio, and favored Regeneron, Vertex and Amgen over Alnylam
fool.com 2 Growth Stocks to Buy in November Without Any Hesitation Vertex and Regeneron started 2026 slowly, but blockbuster results and deep pipelines have both stocks climbing again.
zacks.com REGN Gets FDA Nod for Livsayis in Generalized Myasthenia Gravis Regeneron's Livsayis becomes the first and only siRNA therapy approved by the FDA for generalized myasthenia gravis, offering four subcutaneous doses a year.
benzinga.com Regeneron Wins FDA Nod For Livsayis, 4x-Year GMG Shot The FDA approves Regeneron's Livsayis as the first siRNA therapy for adults with generalized myasthenia gravis, requiring four annual doses.benzinga.com Regeneron Pharmaceuticals To Present New And Updated Data From Hematology Portfolio And Pipeline, At ASH 2026 Annual Meeting Primary analysis from a potentially pivotal trial of Ordspono® (odronextamab) in patients with R/R marginal zone lymphoma (MZL) to be shared in an oral presentation, part of a clinical development…
globenewswire.com Regeneron Highlights New Data Across Malignant and Classical Hematology Programs at American Society of Hematology (ASH) Primary analysis from a potentially pivotal trial of Ordspono ® (odronextamab) in patients with R/R marginal zone lymphoma (MZL) to be shared in an oral presentation, part of a clinical development…
reuters.com US FDA approves Regeneron's drug for generalized myasthenia gravis US FDA approves Regeneron's drug for generalized myasthenia gravis
globenewswire.com Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing Approval based on Phase 3 NIMBLE results demonstrating rapid, deep and sustained disease control that is maintained throughout three-month dosing intervals
zacks.com Regeneron Wins EC Clearance for Libtayo Dosing Flexibility REGN gains EC approval for flexible Libtayo dosing across six cancer indications, potentially improving patient convenience and strengthening its oncology business.
marketbeat.com Regeneron Pharmaceuticals Sees Growth Ahead, Eyes EYLEA HD Syringe Approval Regeneron Pharmaceuticals NASDAQ: REGN expects its three largest growth drivers to continue supporting revenue growth, while planning higher research and development spending and preparing for a…
seekingalpha.com Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies Global Healthcare Conference 2026 Transcript Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies Global Healthcare Conference 2026 Transcript
defenseworld.net Regeneron Pharmaceuticals, Inc. $REGN Position Lifted by Banco Santander S.A. Banco Santander S.A. boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 6.4% during the third quarter, according to its most recent Form 13F filing with the Securities and…
defenseworld.net Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by AlTi Global Inc. AlTi Global Inc. decreased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 75.2% in the third quarter, according to the company in its most recent 13F filing with the SEC. The…benzinga.com Regeneron Pharmaceuticals Says EC Approves Alternative, Flexible Dosing Schedule For Libtayo Across All Approved Skin, Lung And Cervical Cancer Indications Approval introduces an extended dosing regimen of Libtayo 700 mg given every six weeks, following initial 12 weeks of treatment with Libtayo 350 mg every three weeksAlso approved is an option of…
globenewswire.com Libtayo® (cemiplimab) Approved in the European Union (EU) for Extended Dosing and Faster Infusion Times Across Skin, Lung and Cervical Cancer Indications Approval introduces an extended dosing regimen of Libtayo 700 mg given every six weeks, following initial 12 weeks of treatment with Libtayo 350 mg every three weeks Also approved is an option of…
fxempire.com REGN Price Forecast: Rally Faces Resistance After 37% Advance Regeneron shares face growing resistance after a 37% advance, with potential correction targets emerging while the intermediate- and long-term bullish trends remain intact.
247wallst.com 4 Dividend Stocks Retirees Can Buy Before They Go Ex-Dividend in the Week Ahead Four Nasdaq payers hit their ex-dividend dates within two trading days, and one wrong move on timing forfeits the check. Which ones have the cash flow to keep paying, and where does hidden risk lurk…
benzinga.com Regeneron Drug Lowers Standing Heart Rate And Improves Symptoms In Heart Disease Study Regeneron reports Phase 2 PINNACLE trial data showing baloncibart reduces standing heart rate and improves symptoms in adults with POTS.
benzinga.com If You Invested $1000 In Regeneron Pharmaceuticals Stock 15 Years Ago, You Would Have This Much Today Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 8.79% on an annualized basis producing an average annual return of 21.73%. Currently, Regeneron…
benzinga.com Brightview Posts Downbeat Q4 Results, Joins Astronics, Spire Global And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session U.S. futures rose, but BrightView plunged 17.7% after missing earnings and sales estimates; Lightwave Logic and others also fell premarket.benzinga.com Alnylam And Regeneron Says Data Published In The The New England Journal Of Medicine, Reports Up To 80% Reduction In Liver Fat Sustained For 36 Weeks After Single CIDEBsiRNA Dose In MASLD Patients Single administration of CIDEBsiRNA resulted in rapid, deep and durable reductions in liver fat by up to 80% that were sustained through 36 weeksData shared in oral presentation at AASLD The Liver…
benzinga.com Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain? Biotech ETFs face key FDA catalysts as Summit Therapeutics' decision and the Hims-Lilly GLP-1 deal put XLV, IBB and XBI in focus.
benzinga.com Drugmaker CEOs Say AI Alone Can't Cure Diseases, Challenge Silicon Valley's Bold Predictions: 'To Say AI Is Going to Cure Cancer...' Drugmaker executives doubt AI will cure disease soon, saying biology is too complicated.
benzinga.com UnitedHealth, Cleveland-Cliffs, Regeneron Pharmaceuticals And More: CNBC’s ‘Final Trades’ CNBC traders picked RSP, Cleveland-Cliffs, UnitedHealth and Regeneron; REGN surged after strong Q3 earnings, while RSP also gained.benzinga.com Leerink Partners Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $997 Leerink Partners analyst David Risinger maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Market Perform and raises the price target from $835 to $997.
benzinga.com Bernstein Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $812 Bernstein analyst Jeffrey Walch maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Market Perform and raises the price target from $756 to $812.
benzinga.com Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $855 Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $779 to $855.
benzinga.com RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $913 RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Sector Perform and raises the price target from $810 to $913.
benzinga.com Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $982 Truist Securities analyst Gregory Renza maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $780 to $982.
benzinga.com Guggenheim Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1100 Guggenheim analyst Yatin Suneja maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $1030 to $1100.
benzinga.com These Analysts Raise Their Forecasts On Regeneron Pharmaceuticals After Upbeat Q3 Results Regeneron beat Q3 estimates with EPS up 70% and revenue up 36%; analysts raised price targets to as high as $1,175.benzinga.com Wells Fargo Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $925 Wells Fargo analyst Mohit Bansal maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $750 to $925.
benzinga.com Top 3 Health Care Stocks That May Fall Off A Cliff This Quarter Regeneron, AstraZeneca and Exelixis show overbought RSI readings after strong gains, warning momentum-focused investors of potential pullbacks.benzinga.com Evercore ISI Group Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $1075 Evercore ISI Group analyst Cory Kasimov maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and raises the price target from $900 to $1075.
benzinga.com Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday Analysts upgraded MHK and CRWD, downgraded PFSI, cut ABOS’s target, and raised targets for NRXP, REGN and NTSK.benzinga.com Canaccord Genuity Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1175 Canaccord Genuity analyst John Newman maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $922 to $1175.
benzinga.com Cantor Fitzgerald Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $980 Cantor Fitzgerald analyst Carter Gould maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $795 to $980.
benzinga.com Baird Maintains Neutral on Regeneron Pharmaceuticals, Raises Price Target to $875 Baird analyst Brian Skorney maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Neutral and raises the price target from $761 to $875.
benzinga.com B of A Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1030 B of A Securities analyst Tazeen Ahmad maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $908 to $1030.
benzinga.com Alphabet Posts Worst Week Since 2011, Intel Suffers Record Crash as Warsh Sees 'Cracks': This Week on Wall Street Alphabet logs its worst week since 2011 and Intel its worst day ever as the AI trade cracks, while health care posts a record month against the market.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers CareDx (NASDAQ:CDNA) shares rose 22.2% to $87.42 during Friday's regular session. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday.…
benzinga.com Nasdaq Tumbles Over 3%, Chip Stocks Sink: Stock Market Today Intel nears its worst day on record after weak guidance, sinking chip stocks as SMH falls 7.0% and the Nasdaq 100 drops 3.2%.
benzinga.com Regeneron Eyes One of Its Strongest Years Ever, Stock Jumps Regeneron stock hits a 52-week high as earnings surge 70%, revenue jumps 36% and key drugs deliver record sales.
benzinga.com AutoNation, Regeneron Pharmaceuticals, AstraZeneca And Other Big Stocks Moving Higher On Friday U.S. stocks fell Friday, but AutoNation jumped 8% after beating Q3 estimates; OneSpan, Grid Dynamics and others posted double-digit gains.
benzinga.com Regeneron Pharmaceuticals Q3 2026 Earnings Call Transcript Regeneron Pharmaceuticals (NASDAQ:REGN) reported third-quarter financial results on Friday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…benzinga.com Regeneron Pharmaceuticals Q3 Adj. EPS $20.07 Beats $16.19 Estimate, Sales $5.116B Beat $4.542B Estimate Regeneron Pharmaceuticals (NASDAQ:REGN) reported quarterly earnings of $20.07 per share which beat the analyst consensus estimate of $16.19 by 23.97 percent. This is a 69.65 percent increase over…
benzinga.com Top Wall Street Forecasters Revamp Regeneron Pharmaceuticals Expectations Ahead Of Q3 Earnings Regeneron expects Q3 EPS of $16.19 and revenue of $4.56B; extended BARDA’s Inmazeb supply deal as analysts raise price targets.
benzinga.com ExxonMobil, AbbVie On Deck Friday As Energy, Drug Growth Face Test ExxonMobil headlines Friday’s reports, with investors watching whether strong energy production can sustain a sharp earnings recovery. AbbVie, Chevron, AstraZeneca, BP, Sanofi, General Dynamics,…benzinga.com Canaccord Genuity Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $922 Canaccord Genuity analyst John Newman maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $875 to $922.
